Pan-Cancer and Single-Cell Analysis Reveals CENPL As a Cancer Prognosis and Immune Infiltration-Related Biomarker

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Jul 18

PMID 35844598

Authors

Ziyang Feng

Yu Chen

Changjing Cai

Jun Tan

Ping Liu

Yihong Chen

Hong Shen

Shan Zeng

Ying Han

Affiliations

Soon will be listed here.

Abstract

Background: Centromere protein L (CENPL) is an important member of the centromere protein (CENP) family. However, the correlation between CENPL expression and cancer development and immune infiltration has rarely been studied. Here, we studied the role of CENPL in pan-cancer and further verified the results in lung adenocarcinoma (LUAD) through experiments.

Methods: The CENPL expression level was studied with TIMER 2.0 and Oncomine databases. The potential value of CENPL as a diagnostic and prognostic biomarker in pan-cancer was evaluated with the TCGA database and GEPIA. The CENPL mutation character was analyzed using the cBioPortal database. The LinkedOmics and CancerSEA databases were used to carry out the function analysis of CENPL. The role of CENPL in immune infiltration was studied using the TIMER and TISIDB websites. Moreover, the expression of CENPL was detected through RT-qPCR and Western blotting. Immunohistochemistry was used to evaluate the infiltration level of CD8 T cells. Cell proliferation was detected by EdU and CCK8. A flow cytometer was used to analyze the influence of CENPL in cell cycle and apoptosis.

Results: CENPL was increased in most of the cancers. The upregulation and mutation of CENPL were associated with a poorer prognosis in many cancers. The results showed a significant positive correlation between CENPL and myeloid-derived suppressor cell (MDSC) infiltration and a negative correlation between CENPL and T-cell NK infiltration in most of the cancers. CENPL regulated cell proliferation and cell cycle, and was negatively correlated with the inflammation level of LUAD. The experiments suggested that CENPL was increased in LUAD tissue and cell lines. There was a negative correlation between CENPL expression and CD8 T-cell infiltration. The knockdown of CENPL significantly suppressed the expression of CDK2 and CCNE2, and induced G0/G1 arrest and apoptosis of LUAD.

Conclusions: CENPL may function as a potential biomarker and oncogene in pan-cancer, especially LUAD. Furthermore, CENPL was associated with immune cell infiltration in pan-cancer, providing a potential immune therapy target for tumor treatment.

Citing Articles

KDM1A-mediated ZFP64 demethylation activates CENPL to promote epithelial ovarian cancer progression.

Wang J, Fang X, Xing Y, Ding M, Zhu L, Wang M Cytotechnology. 2024; 77(1):10.

PMID: 39628712 PMC: 11609140. DOI: 10.1007/s10616-024-00671-w.

Role of , , and in determining the prognosis of patients with lung adenocarcinoma.

Xu R, Han F, Zhao Y, Liu A, An N, Wang B Transl Lung Cancer Res. 2024; 13(10):2729-2745.

PMID: 39507047 PMC: 11535832. DOI: 10.21037/tlcr-24-696.

Multi-omics analysis identifies BCAT2 as a potential pan-cancer biomarker for tumor progression and immune microenvironment modulation.

Cao Q, Fan J, Zou J, Wang W Sci Rep. 2024; 14(1):23371.

PMID: 39375392 PMC: 11458862. DOI: 10.1038/s41598-024-74441-1.

Co-delivery of siRNA and cisplatin via electrospun Nanofibrous membranes for synergistic treatment of malignant melanoma.

Zhang X, Zheng G, Zhou Z, Zhu M, Tang S Heliyon. 2024; 10(17):e37517.

PMID: 39290263 PMC: 11407083. DOI: 10.1016/j.heliyon.2024.e37517.

SLC8A1, a novel prognostic biomarker and immunotherapy target in RSA and UCEC based on scRNA-seq and pan-cancer analysis.

Chu J, Qin X, Chen W, Xu Z, Xu X Heliyon. 2024; 10(17):e36899.

PMID: 39263055 PMC: 11388753. DOI: 10.1016/j.heliyon.2024.e36899.

References

Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim R, Ong S . Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer. Cancer Res. 2021; 81(12):3295-3308. PMC: 8776246. DOI: 10.1158/0008-5472.CAN-20-3564. View

Oliver A, Lau P, Unsworth A, Loi S, Darcy P, Kershaw M . Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. Front Immunol. 2018; 9:70. PMC: 5797771. DOI: 10.3389/fimmu.2018.00070. View

Forde P, Chaft J, Smith K, Anagnostou V, Cottrell T, Hellmann M . Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018; 378(21):1976-1986. PMC: 6223617. DOI: 10.1056/NEJMoa1716078. View

Shao C, Wang Y, Duan H, Ding P, Zhang Y, Ning J . Mitosis-related gene as a potential biomarker in malignancy. Ann Transl Med. 2022; 9(23):1744. PMC: 8743736. DOI: 10.21037/atm-21-6516. View

Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell M, Tidwell R . Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020; 26(12):1845-1851. PMC: 9768836. DOI: 10.1038/s41591-020-1086-y. View

Farhood B, Najafi M, Mortezaee K . CD8 cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2018; 234(6):8509-8521. DOI: 10.1002/jcp.27782. View

Hinds P . Cdk2 dethroned as master of S phase entry. Cancer Cell. 2003; 3(4):305-7. DOI: 10.1016/s1535-6108(03)00084-9. View

Raskov H, Orhan A, Christensen J, Gogenur I . Cytotoxic CD8 T cells in cancer and cancer immunotherapy. Br J Cancer. 2020; 124(2):359-367. PMC: 7853123. DOI: 10.1038/s41416-020-01048-4. View

Li T, Liu T, Zhu W, Xie S, Zhao Z, Feng B . Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. Clin Med Insights Oncol. 2021; 15:11795549211035540. PMC: 8365012. DOI: 10.1177/11795549211035540. View

10.

Foltz D, Jansen L, Black B, Bailey A, Yates 3rd J, Cleveland D . The human CENP-A centromeric nucleosome-associated complex. Nat Cell Biol. 2006; 8(5):458-69. DOI: 10.1038/ncb1397. View

11.

Meurette O, Mehlen P . Notch Signaling in the Tumor Microenvironment. Cancer Cell. 2018; 34(4):536-548. DOI: 10.1016/j.ccell.2018.07.009. View

12.

Sharma A, Dimitrov S, Hamiche A, Van Dyck E . Centromeric and ectopic assembly of CENP-A chromatin in health and cancer: old marks and new tracks. Nucleic Acids Res. 2018; 47(3):1051-1069. PMC: 6379705. DOI: 10.1093/nar/gky1298. View

13.

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

14.

Zhou H, Bian T, Qian L, Zhao C, Zhang W, Zheng M . Prognostic model of lung adenocarcinoma constructed by the CENPA complex genes is closely related to immune infiltration. Pathol Res Pract. 2021; 228:153680. DOI: 10.1016/j.prp.2021.153680. View

15.

Li Z, Zhang L, Liu D, Yang Z, Xuan D, Zhang Y . Knockdown of NRMT enhances sensitivity of retinoblastoma cells to cisplatin through upregulation of the CENPA/Myc/Bcl2 axis. Cell Death Discov. 2022; 8(1):14. PMC: 8748520. DOI: 10.1038/s41420-021-00622-w. View

16.

Hinds P . A confederacy of kinases: Cdk2 and Cdk4 conspire to control embryonic cell proliferation. Mol Cell. 2006; 22(4):432-3. DOI: 10.1016/j.molcel.2006.05.006. View

17.

Yang J, Dong Z, Ren A, Fu G, Zhang K, Li C . Antibiotic tigecycline inhibits cell proliferation, migration and invasion via down-regulating CCNE2 in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2020; 24(7):4245-4260. PMC: 7171345. DOI: 10.1111/jcmm.15086. View

18.

Herbst R, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios C . Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020; 383(14):1328-1339. DOI: 10.1056/NEJMoa1917346. View

19.

Mellone B, Zhang W, Karpen G . Frodos found: Behold the CENP-a "Ring" bearers. Cell. 2009; 137(3):409-12. PMC: 3192489. DOI: 10.1016/j.cell.2009.04.035. View

20.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View